DPR-MEDIATED H_2O_2 RESISTANCE CONTRIBUTES TO STREPTOCOCCI SURVIVAL IN A CYSTIC FIBROSIS AIRWAY MODEL SYSTEM

Rendi R. Rogers[1], Christopher A. Kesthely[1], Fabrice Jean-Pierre[1,2],
Bassam El Hafi[1], George A. O'Toole[1,#]

[1]Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, 03755
[2]Current Address: Département de Biologie, Université de Sherbrooke, Sherbrooke, QC, Canada

[#]Address correspondence to:
George A. O'Toole, georgeo@dartmouth.edu
Dept. of Microbiology & Immunology
Rm 202 Remsen Building
66 College Street
Geisel School of Medicine at Dartmouth
Hanover, NH 03755
Phone: (603) 650-1248

Running Title: Role for Dpr in a polymicrobial CF model

Keywords: cystic fibrosis, *Streptococcus*, reactive oxygen, peroxide

ABSTRACT

The cystic fibrosis (CF) lung environment is conducive to the colonization of bacteria as

polymicrobial biofilms, which are associated with poor clinical outcomes for persons with CF

(pwCF). *Streptococcus* spp. is highly prevalent in the CF airway, but its role in the CF lung

microbiome is poorly understood. Some studies have shown *Streptococcus* spp. to be associated

with better clinical outcomes for pwCF, while others show that high abundance of *Streptococcus*

spp. is correlated with exacerbations. Our lab previously reported a polymicrobial culture system

consisting of four CF-relevant pathogens that can be used to study microbial behavior in a more

clinically relevant setting. Here, we use this model system to identify genetic pathways that are

important for *Streptococcus sanguinis* survival in the context of the polymicrobial community.

We identified genes related to reactive oxygen species (ROS) as differentially expressed in *S.*

sanguinis monoculture versus growth of this microbe in the mixed community. Genetic studies

identified Dpr as important for *S. sanguinis* survival in the community. We show that Dpr, a

DNA binding ferritin-like protein, and PerR, a peroxide-responsive transcriptional regulator of

Dpr, are important for protecting *S. sanguinis* from phenazine-mediated toxicity in co-culture

with *P. aeruginosa* and when exposed to ROS, both of which mimic the CF lung environment.

Characterizing such interactions in a clinically relevant model system contributes to our

understanding of microbial behavior in the context of polymicrobial biofilm infections.

IMPORTANCE

Streptococcus spp. is recognized as a highly prevalent pathogen in CF airway infections.

However, its role in clinical outcomes for pwCF is poorly understood. Here, we leverage a

polymicrobial community system previously developed by our group to model CF airway

infections as a tool to investigate a *Pseudomonas-Streptococcus* interaction involving ROS. We

show that protection against ROS is required for *S. sanguinis* survival in a clinically relevant

polymicrobial system. Using this model system to study interspecies interactions contributes to

our broader understanding of the complex role of *Streptococcus* spp. in the CF lung.

INTRODUCTION

The cystic fibrosis (CF) airway is characterized by the presence of thick, dehydrated mucus that

impairs mucociliary clearance and creates an environment conducive to bacterial colonization.

Persons with CF (pwCF) commonly develop chronic lung infections that microbiome studies

have shown to be diverse and polymicrobial (1–3). Although streptococci are now recognized as

a central component of the CF lung microbiome (4–7), their specific role in CF lung disease

remains unclear. Previous findings have shown that an increased relative abundance of

streptococci in the lung, including those originating from the oral microflora, corresponds to less

severe impacts on lung disease compared to infection with other CF-associated microbes (5, 6,

8–10). In contrast, other studies have shown that a higher abundance of streptococci is more

likely in pwCF upon receiving treatment for severe airway symptoms (11, 12). The

Streptococcus anginosus group (SAG, also known as the *Streptococcus milleri* group) are

specifically correlated with increased exacerbation when they are the predominant species in the

lung (4, 13–15). Together, these data underscore the complex and multifaceted role of

streptococci in the context of the CF airway (16).

Previous findings indicate that streptococci in the CF lung may interact with other CF pathogens

in ways that could alter bacterial physiology and virulence (2, 10, 17–24). Notably, coculture

experiments have suggested that *Streptococcus* spp. engage in both positive and negative

interactions with the prominent CF pathogen *Pseudomonas aeruginosa*. For example, *P.*

aeruginosa can positively impact *Streptococcus* spp. biofilm formation via secretion of

exopolysaccharides (19, 24). Conversely, *P. aeruginosa* can negatively affect *Streptococcus* spp.

growth via rhamnolipid secretion (20). Furthermore, *Streptococcus* spp. have been shown to

enhance virulence factor production by *P. aeruginosa* (21, 23), but streptococci can also inhibit

P. aeruginosa growth and viability via production of reactive oxygen species (ROS) and reactive

nitrogen species (RNS) (17, 18, 22). It is important to note nearly every study cited here was

performed in different media and under growth conditions that do not necessarily reflect the CF

lung environment, thus it is difficult to determine which of these interactions might be clinically

relevant.

Work from our lab has aimed to address existing gaps in our understanding of polymicrobial

biofilms within the framework of CF infections by using a novel, clinically-informed model

community consisting of four CF-relevant microbes (25). The model community consists of *P.*

aeruginosa, Staphylococcus aureus, Streptococcus sanguinis, and *Prevotella melaninogenica*

cultured in artificial sputum medium (ASM) supplemented with mucin and grown under anoxic

conditions, simulating the mucus plug environment where microbes are often found in the CF

lung (26, 27).

Using the aforementioned co-culture system, we have reported that several tested streptococci

exhibit increased growth when in the presence of other microbial partners (25). Here, in an

attempt to understand the community-specific genes important for the establishment of

streptococci in a polymicrobial environment, we leverage RNA-Seq data from a recent study

involving this polymicrobial community (28) to identify *S. sanguinis* genes that are differentially

expressed when *S. sanguinis* is grown in coculture compared to monoculture. Multiple genes

identified as highly downregulated in coculture are involved in the ROS response. We show that

one of these genes, the DNA-binding ferritin-like protein Dpr, as well as a Fur-family

transcriptional regulator, PerR, a known regulator of Dpr in other streptococci, are important for

protecting *S. sanguinis* in coculture with *P. aeruginosa*, likely via mitigating phenazine- and

H_2O_2-mediated toxicity. These findings suggest that a robust ROS response is a potential key

factor for *S. sanguinis* survival in the CF airway, particularly in the context of a polymicrobial

community.

RESULTS

***S. sanguinis* genes required for the ROS response are differentially expressed in**

monoculture compared to co-culture. We previously performed an RNA-Seq analysis of a

CF-relevant polymicrobial community consisting of *P. aeruginosa* PA14*, S. aureus* Newman*, S.*

sanguinis SK36*,* and *P. melaninogenica* ATCC 25845 (28). This analysis showed that nearly five

hundred *S. sanguinis* genes are significantly differentially expressed when grown in the mixed

community compared to growth as a monoculture. To investigate potential genetic pathways that

contribute to *Streptococcus* microbe-microbe interactions in the CF airway, we identified those

genes most differentially expressed in the mixed community compared to the monoculture

(**Figure S1, Supplemental Table S1**). Our analysis found five genes involved in *S. sanguinis*

response to ROS that are significantly and robustly upregulated in the monoculture when

compared to the mixed community (**Figure 1A**).

Next, we tested the impact of each gene shown in **Figure 1A** on *S. sanguinis* viability when

grown in the mixed community as compared to the monoculture. Mutants were obtained from a

comprehensive SK36 mutant library (29) and grown in a monoculture and mixed culture as

previously described (**Figure 1B**) (25). Of the five mutants tested, only two showed a significant

reduction in viability in the mixed culture compared with the Ssx_*tpx* mutant strain showing a

0.411 $\log_{10}$ reduction in biofilm viable counts and the Ssx_*dpr* mutant showing a 1.675 $\log_{10}$

reduction in biofilm growth quantified by CFUs compared to the WT (**Figure 1C, Figure S2**).

Surprising, despite the higher expression of these genes in monoculture, none of the mutants

tested showed a significant reduction in viability compared to the WT in monoculture (**Figure**

1C). Because the Ssx_*dpr* mutant showed the greatest reduction in viability, we narrowed the

focus of this study to investigate Dpr.

Figure 1. *S. sanguinis* ROS-related genes are differentially expressed in monoculture versus co-culture, and contribute to *S. sanguinis* survival in a mixed community. (**A**) Name and function of genes involved in oxidative stress response that are differentially expressed in monoculture versus the mixed community along with $\log_2$ fold change in the monoculture compared to the four-species mixed community. These genes are all significantly more highly expressed in monoculture versus co-culture. The adjusted P value using a Bonferroni correction is shown in the right-most column. (**B**) Experimental outline of the microbial growth assay used throughout this study. (**C**) Colony forming unit (CFU) counts for mutants grown in monoculture and the mixed community for 24 hrs. MO = monoculture, MX = mixed community. Black lines show wild-type (WT) *S. sanguinis* CFU counts across all experiments. Solid line = monoculture average. Dashed line = mixed community average. CFUs were performed by plating on medium selective for the growth of *Streptococcus* spp. Each data point presented in a column represents the average from at least three technical replicates performed at least on three different days (n=3). Statistical analysis was performed using ordinary one-way ANOVA and Tukey's multiple comparisons posttest with *, $p<0.05$; ****, $p<0.0001$, ns = non-significant. Error bars

Loss of PerR function results in poor *S. sanguinis* growth in the mixed community. It has

been previously shown that PerR functions as a peroxide responsive transcriptional regulator and

is involved in regulating *dpr* gene expression as well as other genes required for the ROS

response in *Streptococcus* spp. (30–33). Therefore, we hypothesized that the observed reduction

in viability of the Ssx_*dpr* mutant in the mixed community may be dependent on PerR

regulation. First, we conducted viability assays as described in the previous section (**Figure 1B**)

with a Ssx_*perR* mutant in parallel with the Ssx_*dpr* mutant (**Figure 2A**) and observed that the

Ssx_*perR* mutant mirrors the phenotype of the Ssx_*dpr* mutant. These findings indicated that

PerR may positively regulate the *dpr* gene in *S. sanguinis*. Complementation of the Ssx_*dpr* or

Ssx_*perR* mutant restored growth in the mixed community to a level not statistically

significantly different from the growth of these mutants in monoculture (**Figure 2A**).

Next, to test the pattern of growth of these mutants in the mixed community over time, we

conducted the same viability assay (**Figure 2A**), this time quantifying CFUs at 6, 12, 18, and 24

hours post-inoculation (**Figure 2B**). While wild-type (WT) *S. sanguinis* grows throughout the

24-hour incubation period, we observed that both the Ssx_*dpr* and Ssx_*perR* mutants grow at a

comparable rate to the WT for the first six hours, after which their growth plateaus. These data

further support the hypothesis that loss of function of PerR and Dpr is responsible for the

observed reduction in viable bacterial counts.

Figure 2. Loss of PerR, a *dpr* repressor, results in poor *S. sanguinis* growth in the mixed community. (**A**) CFU counts for mutants and their complements grown in monoculture and the mixed community. MO = monoculture, MX = mixed community, C = complemented in the mixed community. Black lines show wild-type (WT) *S. sanguinis* CFU counts across all experiments. Solid line = monoculture average. Dashed line = mixed community average. CFUs were performed by plating on medium selective for the growth *Streptococcus* spp. Each data point represents the average from at least three technical replicates performed at least on three different days (n = 3). Statistical analysis was performed using ordinary one-way ANOVA and Tukey's multiple comparisons posttest with *, p<0.05; ****, p<0.0001, ns = non-significant. Statistics shown here compare mutant growth to WT growth in the same condition (MO to MO, MX to MX, MX to C). Error bars represent SD. CFU counts for other bacteria in the mixed community are shown in **Supplemental Figure S3**. (**B**) CFU counts for mutants measured every six hours over the course of 24 hours. CFUs were performed by plating on medium selective for the growth of *Streptococcus* spp. Each data point represents the average from at least three technical replicates performed at least on three different days (n = 3). Statistical analysis was performed using ordinary one-way ANOVA and Tukey's multiple comparisons posttest with *, p<0.05; **, p<0.01; ****, p<0.0001, no notation = non-significant. Error bars represent SD. (**C**) Log₂ fold change in expression of *dpr, perR,* and *sodA* genes in the Ssx_*dpr,* Ssx_*perR,* and Ssx_*sodA* mutant backgrounds compared to the WT, which is represented by the dashed line. Change in gene expression was calculated using the $\Delta\Delta C_T$ method. Each data point represents the average from at least three technical replicates performed at least on three different days (n = 3). Statistical analysis was performed using ordinary one-way ANOVA and Tukey's multiple comparisons posttest with *, p<0.05; ****, p<0.0001, ns = non-significant. Error bars represent SD.

PerR negatively regulates *dpr* gene expression. To test the hypothesis that PerR is a positive

regulator of *dpr*, we quantified expression of *dpr* and another known PerR-regulated gene, *sodA*,

in both the WT and Ssx_*perR* backgrounds using qPCR. We observed that *dpr* expression is

significantly increased in the Ssx_*perR* background, while *sodA* expression, as expected (31), is

significantly decreased (**Figure 2C**). These data indicate that PerR functions to repress the

transcription of *dpr* in *S. sanguinis*. Furthermore, this result suggests that the observed loss of

growth phenotypes of the Ssx_*dpr* and Ssx_*perR* mutants in the community may result from

different mechanisms. We address this idea further in the Discussion. We also note that the

Ssx_*dpr* mutant showed no change in *sodA* or *perR* gene expression, while mutating *sodA* does

result in a modest by significant increase in *perR* gene expression.

***P. aeruginosa* PA14 secreted phenazines cause poor growth for the *perR* and *dpr* mutants**.

To investigate the mechanism by which incubation in the polymicrobial community is causing

the observed defect in the growth of the Ssx_*dpr* and Ssx_*perR* mutants, we conducted pairwise

co-culture assays and found that growing the Ssx_*dpr* and Ssx_*perR* mutants with WT *P.*

aeruginosa alone is sufficient to reproduce the phenotype observed in the four-species mixed

community (**Figure S4**).

Next, we cultured the Ssx_*dpr* and Ssx_*perR* mutants in the presence of sterilized, cell-free

supernatant from WT *P. aeruginosa* to test if secreted factors cause reduced growth for the

Ssx_*dpr* and Ssx_*perR* mutants. The Ssx_*dpr* mutant shows a significant reduction in CFU

counts in the presence of *P. aeruginosa* supernatant, although the defect is lesser than what is

observed in the presence of live *P. aeruginosa* (**Figure 3A**). Interestingly, the Ssx_*perR* mutant

also showed a reduction in CFU counts, although this reduction was not statistically significant

(**Figure 3A**). These data suggest that a secreted factor might account for, at least in part, the

reduced viability of the Ssx_*dpr* and Ssx_*perR* mutants. Based on these data, we sought to

investigate which *P. aeruginosa* secreted factors might be responsible for the observed growth

defects of these mutants in the community.

Previous work showed that *P. aeruginosa* phenazine production is correlated with increased

production of H_2O_2 (34). Based on this literature, we hypothesized that disrupting phenazine

production by *P. aeruginosa* would rescue the growth defect observed in the Ssx_*dpr* and

Ssx_*perR* mutants in co-culture. We also chose to test other factors known to be secreted by *P.*

aeruginosa, particularly those with known roles in microbe-microbe interactions and virulence

factors, including the *Pseudomonas* quinolone signal (PQS) (35, 36). Of the nine mutants tested

(**Figure S5**), the *P. aeruginosa* PA14 *ΔphzA1-G1,A2-G2* mutant (37), which lacks the ability to

produce phenazines, and the *P. aeruginosa* PA14 Δ*pqsA* (38)*,* which lacks the ability to produce

PQS, were the only mutants that conferred a significant increase in viability for the Ssx_*dpr* or

Ssx_*perR* mutants (**Figure S5**). The data show that eliminating production of phenazines, but not

PQS, rescues the reduced viability phenotype for both Ssx_*dpr* and Ssx_*perR* mutants (**Figure**

3B).

Figure 3. *P. aeruginosa* secreted phenazines cause poor growth in Ssx_*perR* and Ssx_*dpr* mutants. (A) CFU counts for *S. sanguinis* mutants grown in ASM supplemented with *P. aeruginosa* supernatant (*Pa* sup) or with a non-supernatant control (no sup). Black lines show wild-type (WT) *S. sanguinis* CFU counts across all experiments. Solid line = monoculture average. Dashed line = mixed community average. CFUs were performed by plating on medium selective for the growth of *Streptococcus* spp. Each data point represents the average from at least three technical replicates performed at least on three different days (n = 3). Statistical analysis was performed using ordinary one-way ANOVA and Tukey's multiple comparisons posttest with *, p<0.05; ****, p<0.0001, ns = non-significant. Error bars represent SD. (**B**) CFU counts for *S. sanguinis* mutants grown in co-culture with WT *P. aeruginosa* (+ *Pa*), a *P. aeruginosa* phenazine mutant (+ *PaΔΔphz*), or a *P. aeruginosa* quinolone signal mutant (+ *PaΔΔpqs*). CFUs were performed by plating on medium selective for the growth *Streptococcus* spp. Each data point represents the average from at least three technical replicates performed at least on three different days (n = 3). Statistical analysis was performed using ordinary one-way ANOVA and Tukey's multiple comparisons posttest with *, p<0.05; ****, p<0.0001, ns = non-significant. Error bars represent SD. CFU counts for all *S. sanguinis,* and *P. aeruginosa* strains tested in co-culture are shown in **Supplemental Figure S5**. (**C**) CFU counts for *S. sanguinis* WT and mutants grown in ASM supplemented with 50 uM pyocyanin (+ PYO), 50 uM phenazine-1-carboxylic acid (+ PCA), or 0.1% H_2O_2. CFUs were performed by plating on medium selective for the growth *Streptococcus* spp. Each data point represents the average from at least three technical replicates performed at least on three different days (n = 3). Statistical analysis was performed using ordinary one-way ANOVA and Tukey's multiple comparisons posttest with *, p<0.05; ****, p<0.0001, ns = non-significant. Error bars represent SD. (**D**) A model demonstrating a *P. aeruginosa-S. sanguinis* interaction. In this study, we show evidence supporting the hypothesis that Dpr and PerR are important in protecting *S. sanguinis* from H_2O_2 formed as a downstream product of *P. aeruginosa* secreted phenazines.

We next tested the effects of exogenous phenazine molecules pyocyanin (PYO) and phenazine-

1-carboxylic acid (PCA) as well as hydrogen peroxide (H_2O_2) under our standard model

conditions. We found that PYO does not cause a significant viability defect for the Ssx_*dpr* and

Ssx_*perR* mutants compared to the wild type (WT), while PCA causes a significant viability

defect in the Ssx_*perR* mutant and a small, but non-significant reduction for the Ssx_*dpr* mutant

compared to the WT. Peroxides, which can be generated by phenazines (34) causes a significant

viability defect for both Ssx_*dpr* and Ssx_*perR* mutants compared to the WT **(Figure 3C)**. These

data taken together, along with previous studies (21, 34) support the model depicted in **Figure**

3D. That is, *P. aeruginosa* overexpresses redox-active phenazines in co-culture with

Streptococcus spp. which likely results in higher levels of H_2O_2, and both PerR and Dpr are

important for *S. sanguinis* survival in this interaction.

DISCUSSION

Building on previous knowledge of streptococcal interactions, we used a clinically-informed

model community that simulates the CF lung environment to identify an important mechanism

for *S. sanguinis* survival in the context of a CF model of polymicrobial infection. We showed

that at a 24h timepoint, the *dpr* gene, encoding a DNA-binding ferritin-like protein, is robustly

down-regulated in the mixed community setting but, when mutated, causes a defect in *S.*

sanguinis SK36 viability in the mixed community (**Figure 1**). The *dpr* gene shows relatively

high expression in monoculture, yet, when mutated, shows no growth defect compared to the

WT when grown in monoculture using the CF-like conditions of ASM under anaerobic

conditions. It is important to note that our transcriptional study only includes data collected at 24

hours post-incubation (39), while our time course data shown in **Figure 2B** suggests that *dpr*

expression is important for *S. sanguinis* survival in the first 12 hours of growth. Furthermore,

transcriptional data from the same study suggests that *P. aeruginosa* and *S. aureus* also

apparently respond to oxidative stress in monoculture compared to the mixed community.

Notably, in *S. aureus*, a thioredoxin reductase, *trxA*, and superoxide dismutase, *sodM*, are highly

expressed in the mixed community compared to the monoculture. Furthermore, our

transcriptional data indicate that for *S. sanguinis* SK36 there may be a reduction in ROS

exposure, but even this reduced amount can be toxic to a cell lacking PerR or Dpr.

Here, we have begun to explore the mechanism(s) whereby the polymicrobial community causes

a viability defect in the Ssx_*dpr* and Ssx_*perR* mutants. Based on previous work (34), we

hypothesized that *P. aeruginosa* secreted, redox-active phenazines might be a contributor to the

observed phenotype. Our data support this hypothesis, as blocking pyocyanin production via

mutation of the *phz* genes successfully rescues the reduced growth phenotype of the Ssx_*dpr* and

Ssx_*perR* mutants (**Figure 3A**). Similarly, exposing these mutants to the commercially available

phenazine pyocyanin also reduced their viability compared to the WT. Consistent with our

findings here, we showed previously that growth of a *P. aeruginosa* PA14 mutant in this same

mixed community system produced phenazines ((25).

Our data also show that the addition of H_2O_2 can cause a reduction in the viability of the Ssx_*dpr*

and Ssx_*perR* mutants (**Figure 3C**). Previous findings demonstrated that *P. aeruginosa* strains

that overproduce pyocyanin display enhanced H_2O_2 generation, cell lysis, and eDNA release,

while strains that are unable to produce pyocyanin generate negligible amounts of H_2O_2 and

released less eDNA (34). It is thought that pyocyanin promotes eDNA release in *P. aeruginosa*

by inducing cell lysis mediated via H_2O_2 production, and the eDNA in turn facilitates *P.*

aeruginosa biofilm formation ((34, 40–42). The correlation between increased phenazine

production and elevated H_2O_2 levels in *P. aeruginosa* provided a rationale for the observed

phenotype of the *S. sanguinis* Ssx_*dpr* and Ssx_*perR* mutants. That is, it may not be phenazine

toxicity directly but rather phenazine-induced H_2O_2 production that require PerR- or Dpr-

mediated protection. Our data demonstrate that both PerR and Dpr play an important role in

protecting *S. sanguinis*, a catalase-negative bacteria, from H_2O_2.

Previous reports show that Fur-family transcriptional regulators PerR and OxyR can act as

positive or negative regulators of oxidative stress response genes, including *dpr* and *sodA* (31,

32, 43–47). Our data shows that the Ssx_*perR* mutant phenotype in the mixed community

mirrors that of the Ssx_*dpr* mutant (**Figure 2**). Therefore, we hypothesized that the observed

viability reduction in the mixed community for both of these mutants relies on PerR regulation of

dpr. However, our gene expression data suggests that PerR is a negative regulator of *dpr* under

these conditions (**Figure 2C**). These findings indicate that the loss of viability in the Ssx_*perR*

mutant may not be caused by a reduction in *dpr* expression. Interestingly, our findings also show

that *sodA* expression is decreased in the Ssx_*perR* mutant, indicating that PerR is a positive

regulator of *sodA* under these conditions (**Figure 2C**). However, a Ssx_*sodA* mutant does not

show a reduction in viability in the mixed community (**Figure 1C**). Taken together, these data

suggest that the loss of viability in the Ssx_*perR* mutant could result from a reduction in

expression of a combination of PerR-induced genes. Alternatively, it is possible that the

increased expression of *dpr* in the Ssx_*perR* mutant contributes to the observed Ssx_*perR* mutant

phenotype by an unknown mechanism. Altogether, our findings suggest that further investigation

of the PerR regulon is necessary to understand the complex inter-microbe dynamics involving

streptococci in the CF airway.

Our results also suggest that phenazine and/or H_2O_2 production could be an antagonistic tactic

employed by *P. aeruginosa* to compete with streptococci and other microbes in the CF airway.

Dps-family proteins, the structure and function of which have been extensively studied across

many genera of bacteria, but especially *E. coli*, have been shown to provide multifaceted

protection to cells through DNA binding, iron sequestration, and its ferroxidase activity (48–53).

Specifically in streptococci, previous studies have shown that strains without functioning Dps-

family proteins, such as Dpr, display hypersensitivity to H_2O_2. Protection from H_2O_2 is mediated

through the Dpr proteins iron binding activity (44, 54, 55). Other genetic factors have also been

shown to contribute to H_2O_2 protection in streptococci, such as thiol peroxidases, superoxide

dismutases, and NADH oxidases ((33, 56, 57). However, our data showing a lack of a phenotype

for the thiol peroxidase or the superoxide dismutase mutants of *S. sanguinis* (**Figure 1**) suggests

that PerR or Dpr-mediated H_2O_2 resistance are the most important mechanisms of ROS

protection for *S. sanguinis* SK36 in our clinically relevant model.

Interestingly, our findings here complement previous studies showing that *Streptococcus* spp.

can also negatively impact *P. aeruginosa* growth and viability via production of ROS and

reactive nitrogen species (RNS) (17, 18). It is important to note that these previous studies were

done in Todd-Hewit broth (THB) under aerobic growth conditions; thus, differences in the

observed microbial interaction among these studies may be attributable to differential growth

conditions.

In conclusion, this research contributes to our understanding of the intricate microbial

interactions within the CF lung microbiome, emphasizing the role of *S. sanguinis* SK36 ROS

response in the presence of *P. aeruginosa*. Previous findings indicating that lung microbiome

composition can have significant effects on clinical outcome for pwCF (6, 8–10) underscoring

the need for a better understanding of microbial dynamics for the development of effective

interventions in the challenging landscape of CF lung disease. There are clinical data implicating

that high *Streptococcus* abundance can lead to varying clinical outcomes, some positive and

some negative for pwCF (4, 5, 11–15). Gaining a deeper understanding of streptococci dynamics

in the CF lung could shed light on why the current data presents such contradictory results.

Finally, we argue that continued study of microbe-microbe interactions, and further exploration

into the broader implications of these interactions and their clinical relevance, is necessary to

advance the capacity to manage and effectively treat the chronic infections associated with cystic

fibrosis and other chronic airway infections.

MATERIALS AND METHODS

Bacterial strains and culture conditions. *P. aeruginosa* PA14*, S. aureus* Newman*, S.*

sanguinis SK36*,* and *P. melaninogenica* ATCC 25845 strains used in this study are listed in

Supplemental Table S2. All strains were cultivated as previously described (25) *P. aeruginosa*

and *S. aureus* cultures were grown in tryptic soy broth (TSB) with shaking at 37°C. *P.*

melaninogenica cultures were grown in TSB supplemented with 0.5% yeast extract (YE), 5

µg/mL hemin, 2.85 mM L-cysteine hydrochloride, and 1 µg/mL menadione (*Prevotella* growth

medium [PGM]). *S. sanguinis* overnight cultures were grown in Todd-Hewitt broth

supplemented with 0.5% YE (THY) at 37°C with 5% CO_2. Artificial sputum medium with

5mg/mL mucin (ASM) was prepared as previously reported (25) and supplemented with 100

mM 3-morpholinopropane-1-sulfonic acid (MOPS) adjusted to a pH of 6.80.

Complementation constructs for *S. sanguinis* mutants. For complementation of each targeted

S. sanguinis gene, the suicide vector pJFP126 was used to allow for the insertion of

complementing genes into an ectopic chromosomal site (*SSA_0169*) via homologous

recombination and expression of each gene is under the control of an IPTG inducible promoter

hyper-spank as previously reported (58). Primers and plasmids are reported in **Supplemental**

Table S2.

Statistical analysis. Data visualization and statistical analysis were performed using GraphPad

Prism 9. The statistical test used and the resulting P value are listed in the appropriate figure

legend or in the text.

Microbial growth assays. Culture experiments were performed as previously described by (25)

with modifications. Cells from overnight liquid cultures of each strain being used were

individually collected and washed twice (for *P. aeruginosa* and *S. aureus*) or once (for *S.*

sanguinis and *P. melaninogenica*) in sterile phosphate-buffered saline (PBS) by centrifuging at

$10,000 \times g$ for 2 minutes. After the final wash, cells were resuspended in the ASM base (without

mucin). The optical density (OD_{600}) was then measured for each bacterial suspension and diluted

to an OD_{600} of 0.2 in ASM. Monocultures and co-cultures were prepared from the $OD_{600} = 0.2$

suspensions and further diluted to a final OD_{600} of 0.01 for each microbe in ASM. A polystyrene

flat-bottom 96-well plate was inoculated with 100 µL of bacterial suspension for each

monoculture and co-culture condition in triplicate. Plates were incubated using an AnaeroPak-

Anaerobic container with a GasPak sachet (ThermoFisher) at 37°C for 24 hours. After

incubation, unattached cells were aspirated with a multichannel pipette. Pre-formed biofilms

were then washed once with sterile PBS and then resuspended in 50 µL PBS using a sterile 96-

pin replicator. Each culture was 10-fold serially diluted and plated on selective media to quantify

colony forming units (CFUs), as previously reported (25).

Time course assays. Cultures for time course assays were prepared as described in the

'Microbial growth assays' section above. A separate 96-well plate was inoculated for each time

point to be measured. At 6, 12, 18 and 24 hours, biofilms from one 96-well plate were collected

and plated to quantify CFUs as described in 'Microbial growth assays.' Experiments were

performed in triplicate on different days.

qPCR assay. For qPCR experiments, *S. sanguinis* monocultures were cultivated as described

above in the 'Microbial growth assays' section. At 24 hours, bacterial lysis and RNA extraction

were performed following the protocols outlined in the RNeasy Mini Kit (Qiagen). 20μL

mutanolysin (Sigma-Aldrich) was added to the lysozyme solution to aid cell lysis. RNA was

treated with DNAse using the Ambion TURBO DNA-free Kit (ThermoFisher) and quantified by

Nanodrop. 500ng of total RNA was reverse-transcribed using the RevertAid First Strand cDNA

Synthesis Kit (ThermoFisher). Gene expression was quantified using the 2X iQ SYBR Green

supermix (Bio-Rad). All primers used for qPCR are listed in **Supplemental Table S2**. Reactions

containing non-reverse-transcribed RNA and no template were used as controls. We used

transcriptional data from our lab's previously reported RNA-Seq analysis to select a reference

gene that shows minimal differential expression across conditions in a CF-relevant polymicrobial

model system (28). *ntpA* , a V-type sodium ATPase catalytic subunit A, was selected from these

data and used to normalize RNA samples. Relative gene expression was calculated using the

$\Delta\Delta C_T$ method.

Phenazine and ROS response assays.   A 20 mM PYO (Sigma) stock and a 20 mM PCA

(Sigma) stock were each prepared in 100% DMSO. We used commercially available 30% stock

solution of H_2O_2 (Fisher). To test phenazine and ROS response, *S. sanguinis* monocultures were

grown as described in 'Microbial growth assays' for 24 hours. After the 24-hour incubation,

unattached cells were aspirated with a multichannel pipette and discarded. 100μL ASM

supplemented with 50uM, 150uM or 300uM of the phenazines pyocyanin or phenazine-

carboxilic acid (PCA) or 0.1%, 0.2%, and 0.3% H_2O_2, depending on the condition, was added to

wells, in triplicate. ASM supplemented with 0.5% DMSO was used as a control. The cultures

were then incubated for an additional 24 hours in anoxic conditions at 37°C. After 48 total hours

of incubation, biofilm CFUs were quantified as described in the 'Microbial growth assays'

section. Experiments were performed in triplicate on different days.

Supernatant assays. To test effects of supernatant, *S. sanguinis* monocultures were prepared as

described in 'Microbial growth assays' with modifications. The OD_{600} of 0.2 for bacterial

suspensions were diluted into medium consisting of 50% ASM and 50% prepared supernatant.

Biofilm CFUs were quantified at 24 hours as described in the 'Microbial growth assays' section.

Experiments were performed in triplicate on different days.

Supernatant was prepared by growing a full 96-well plate containing either a mix of *P.*

aeruginosa, S. aureus, S. sanguinis, and *P. melananogenica*, or a monoculture of *P. aeruginosa*,

depending on the experimental condition. These cultures were prepared as described in

'Microbial growth assays.' A 96-well plate containing uninoculated ASM was prepared as

described below to use as a 'no supernatant' control. After a 24-hour incubation, the unattached

cultures were aspirated with a multichannel pipette and transferred to sterile 2.0 mL microtube.

Samples were then centrifuged at 16,000 *x g* for 10 minutes. The liquid portion was then

removed from the microtube and passed through a 0.22 μm filter. The prepared cell-free

supernatant was immediately added to ASM and inoculated per the methods described above.

Sterility of the prepared supernatants was confirmed by spotting 5µL of the supernatant onto two

TSB and two blood agar plates that were then incubated both aerobically and anaerobically at

37°C for 24 hours.

ACKNOWLEDGEMENTS. This work was supported by National Institutes of Health (R01

AI155424) to G.A.O.

LITERATURE CITED
1.   LiPuma J. 2012. The new microbiology of cystic fibrosis: It takes a community. *Thorax*

67:851-852.

2.   LiPuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. *Clin Microbiol*

Rev 23:299-323.

3.   O'Toole GA. 2018. Cystic fibrosis airway microbiome: Overturning the old, opening the

way for the new. *J Bacteriol* 200:e00561-17.

4.   Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. 2008. A

polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in

cystic fibrosis patients. *Proc Natl Acad Sci USA* 105:15070-15075.

5.   Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, Morrison HG,

Paster BJ, O'Toole GA. 2012. Prevalence of streptococci and increased polymicrobial

diversity associated with cystic fibrosis patient stability. *J Bacteriol* 194:4709–4717.

6.   Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, Zhang Y,

Surendra A, Gong Y, Elizabeth Tullis D, Yau YCW, Waters VJ, Hwang DM, Guttman

DS. 2015. Lung microbiota across age and disease stage in cystic fibrosis. *Sci Rep*

5:10241.

7.   Mahboubi MA, Carmody LA, Foster BK, Kalikin LM, VanDevanter DR, LiPuma JJ.

2016. Culture-based and culture-independent bacteriologic analysis of cystic fibrosis

respiratory specimens. *J Clin Microbiol* 54:613–619.

8.   Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M,

O'Callaghan G, Shanahan F, Murphy DM, O'Connor OJ, Shortt CA, Tunney MM,

Eustace JA, Maher MM, Elborn JS, Plant BJ. 2018. CORK study in cystic fibrosis:

Sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with

Ivacaftor. *Chest* 153:395–403.

9.   Acosta N, Heirali A, Somayaji R, Surette MG, Workentine ML, Sibley CD, Rabin HR,

Parkins MD. 2018. Sputum microbiota is predictive of long-term clinical outcomes in

young adults with cystic fibrosis. *Thorax* 73:1016–1025.

10. Hampton TH, Thomas D, Van Der Gast C, O'toole GA, Stanton BA. 2021. Mild cystic

fibrosis lung disease is associated with bacterial community stability. *Microbiol Spectr*

9:e0002921.

11. Shoemark A, Shteinberg M, De Soyza A, Haworth CS, Richardson H, Gao Y, Perea L,

Dicker AJ, Goeminne PC, Cant E, Polverino E, Altenburg J, Keir HR, Loebinger MR,

Blasi F, Welte T, Sibila O, Aliberti S, Chalmers JD. 2022. Characterization of

eosinophilic bronchiectasis a European multicohort study. *Am J Respir Crit Care Med*

205:894–902.

12. Broderick DTJ, Waite DW, Marsh RL, Camargo CA, Cardenas P, Chang AB, Cookson

WOC, Cuthbertson L, Dai W, Everard ML, Gervaix A, Harris JK, Hasegawa K, Hoffman

LR, Hong SJ, Josset L, Kelly MS, Kim BS, Kong Y, Li SC, Mansbach JM, Mejias A,

O'Toole GA, Paalanen L, Pérez-Losada M, Pettigrew MM, Pichon M, Ramilo O,

Ruokolainen L, Sakwinska O, Seed PC, van der Gast CJ, Wagner BD, Yi H, Zemanick

ET, Zheng Y, Pillarisetti N, Taylor MW. 2021. Bacterial signatures of paediatric

respiratory disease: An individual participant data meta-analysis. *Front Microbiol*

12:711134.

13. Parkins MD, Sibley CD, Surette MG, Rabin HR. 2008. The Streptococcus milleri group -

An unrecognized cause of disease in cystic fibrosis: A case series and literature review.

Pediatr Pulmonol 43:490–497.

14. Sibley CD, Grinwis ME, Field TR, Parkins MD, Norgaard JC, Gregson DB, Rabin HR,

Surette MG. 2010. McKay agar enables routine quantification of the "*Streptococcus*

milleri" group in cystic fibrosis patients. *J Med Microbiol* 59:534–540.

15. Cade A, Denton M, Brownlee KG, Todd N, Conway SP. 1999. Acute bronchopulmonary

infection due to Strepto*coccus milleri* in a child with cystic fibrosis. *Arch Dis Child*

80:278-279.

16. Scott JE, O'Toole GA. 2019. The yin and yang of *Streptococcus* lung infections in cystic

fibrosis: A model for studying polymicrobial interactions. *J Bacteriol* 201115-119.

17. Scoffield JA, Wu H. 2015. Oral streptococci and nitrite-mediated interference of

Pseudo*monas aeruginosa*. *Infect Immun* 83:101–107.

18. Scoffield JA, Wu H. 2016. Nitrite reductase is critical for *Pseudomonas aeruginosa*

survival during co-infection with the oral commensal *Streptococcus parasanguinis*.

Microbiol (Reading) 162:376–383.

19. Scoffield JA, Duan D, Zhu F, Wu H. 2017. A commensal streptococcus hijacks a

Pseudomonas aeruginosa exopolysaccharide to promote biofilm formation. *PLoS Pathog*

13:e1006300.

20.   Price KE, Naimie AA, Griffin EF, Bay C, O'Toole GA. 2016. Tobramycin-treated

Pseudomonas aeruginosa PA14 enhances *Streptococcus constellatus* 7155 biofilm

formation in a cystic fibrosis model system. *J Bacteriol* 198:237–247.

21.   Duan K, Dammel C, Stein J, Rabin H, Surette MG. 2003. Modulation of *Pseudomonas*

aeruginosa gene expression by host microflora through interspecies communication. *Mol*

Microbiol 50:1477–1491.

22.   Whiley RA, Fleming E V., Makhija R, Waite RD. 2015. Environment and colonisation

sequence are key parameters driving cooperation and competition between *Pseudomonas*

aeruginosa cystic fibrosis strains and oral commensal streptococci. *PLoS One*

10:e0115513.

23.   Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, Rabin HR, Surette MG. 2008.

Discerning the complexity of community interactions using a *Drosophila* model of

polymicrobial infections. *PLoS Pathog* 4:e1000184.

24.   Stoner SN, Baty JJ, Scoffield JA. 2022. *Pseudomonas aeruginosa* polysaccharide Psl

supports airway microbial community development. *ISME J* 16:1730–1739.

25.   Jean-Pierre F, Hampton TH, Schultz D, Hogan DA, Groleau MC, Déziel E, O'toole GA.

2023. Community composition shapes microbial-specific phenotypes in a cystic fibrosis

polymicrobial model system. *Elife* 12:e81604.

26.   Palmer KL, Aye LM, Whiteley M. 2007. Nutritional cues control *Pseudomonas*

aeruginosa multicellular behavior in cystic fibrosis sputum. *J Bacteriol* 189:8079–87.

27.   Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G,

Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Döring G. 2002.

Effects of reduced mucus oxygen concentration in airway *Pseudomonas* infections of

cystic fibrosis patients. *J Clin Inves* 109:317–325.

28. Kesthely CA, Rogers RR, El Hafi B, Jean-Pierre F, O'Toole GA. 2023. Transcriptional

profiling and genetic analysis of a cystic fibrosis airway-relevant model shows

asymmetric responses to growth in a polymicrobial community. *Microbiol Spectr* 11:201-

223.

29. Xu P, Ge X, Chen L, Wang X, Dou Y, Xu JZ, Patel JR, Stone V, Trinh M, Evans K,

Kitten T, Bonchev D, Buck GA. 2011. Genome-wide essential gene identification in

Streptococcus sanguinis. *Sci Rep* 1:125.

30. Brenot A, King KY, Caparon MG. 2005. The PerR regulon in peroxide resistance and

virulence of *Streptococcus pyogenes*. *Mol Microbiol* 55:221–234.

31. Ricci S, Janulczyk R, Björck L. 2002. The regulator PerR is involved in oxidative stress

response and iron homeostasis and is necessary for full virulence of *Streptococcus*

pyogenes. *Infect Immun* 70:4968–4976.

32. Wang CH, Chiang-Ni C, Kuo HT, Zheng PX, Tsou CC, Wang S, Tsai PJ, Chuang WJ, Lin

YS, Liu CC, Wu JJ. 2013. Peroxide responsive regulator PerR of group A streptococcus is

required for the expression of phage-associated DNase Sda1 under oxidative stress. *PLoS*

One 8:e81882.

33. Tong H, Dong Y, Wang X, Hu Q, Yang F, Yi M, Deng H, Dong X. 2020. Redox-

Regulated adaptation of *Streptococcus oligofermentans* to hydrogen peroxide stress.

mSystems 5:e00006-20.

34.   Das T, Manefield M. 2013. Phenazine production enhances extracellular DNA release via

513   hydrogen peroxide generation in *Pseudomonas aeruginosa*. *Commun Integr Biol*

514   6:e23570.

515   35.   Scott JE, Li K, Filkins LM, Zhu B, Kuchma SL, Schwartzman JD, O'Toole GA. 2019.

516   *Pseudomonas aeruginosa* can inhibit growth of streptococcal species via siderophore

517   production. *J Bacteriol* 201:e00014-19.

518   36.   Lin J, Cheng J, Wang Y, Shen X. 2018. The *Pseudomonas* quinolone signal (PQS): Not

519   just for quorum sensing anymore. *Front Cell Infect Microbiol* 8:230.

520   37.   Dietrich LEP, Price-Whelan A, Petersen A, Whiteley M, Newman DK. 2006. The

521   phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of

522   *Pseudomonas aeruginosa*. *Mol Microbiol* 61:1308–1321.

523   38.   Lépine F, Dekimpe V, Lesic B, Milot S, Lesimple A, Mamer OA, Rahme LG, Déziel E.

524   2007. PqsA is required for the biosynthesis of 2,4-dihydroxyquinoline (DHQ), a newly

525   identified metabolite produced by *Pseudomonas aeruginosa* and *Burkholderia*

526   *thailandensis*. *Biol Chem* 388:839–845.

527   39.   Kesthely CA, Rogers RR, Hafi BE, Jean-Pierre F, O'Toole GA. 2023. Transcriptional

528   profiling and genetic analysis of a cystic fibrosis airway-relevant model shows

529   asymmetric responses to growth in a polymicrobial community. *Microbiol Spectr*

530   11:e02201-23.

531   40.   Webb JS, Thompson LS, James S, Charlton T, Tolker-Nielsen T, Koch B, Givskov M,

532   Kjelleberg S. 2003. Cell death in *Pseudomonas aeruginosa* biofilm development. *J*

533   *Bacteriol* 185:4585–4592.

534   41.   Allesen-Holm M, Barken KB, Yang L, Klausen M, Webb JS, Kjelleberg S, Molin S,

535   Givskov M, Tolker-Nielsen T. 2006. A characterization of DNA release in *Pseudomonas*

536   *aeruginosa* cultures and biofilms. *Mol Microbiol* 59:1114–1128.

537   42.   Das T, Manefield M. 2012. Pyocyanin promotes extracellular DNA release in

538   *Pseudomonas aeruginosa*. *PLoS One* 7:e46718.

539   43.   Brenot A, King KY, Caparon MG. 2005. The PerR regulon in peroxide resistance and

540   virulence of *Streptococcus pyogenes*. *Mol Microbiol* 55:221–234.

541   44.   Fujishima K, Kawada-Matsuo M, Oogai Y, Tokuda M, Torii M, Komatsuzawa H. 2013.

542   Dpr and Sod in *Streptococcus mutans* are involved in coexistence with *S. sanguinis*, and

543   PerR is associated with resistance to H_2O_2. *Appl Environ Microbiol* 79:1436–1443.

544   45.   Altuvia S, Almirón M, Huisman G, Kolter R, Storz G. 1994. The *dps* promoter is

545   activated by OxyR during growth and by IHF and sigma S in stationary phase. *Mol*

546   *Microbiol* 13:265–72.

547   46.   Yoo AY, Kim SW, Yu JE, Kim YH, Cha J, Oh J-I, Eo SK, Lee JH, Kang HY. 2007.

548   Requirement of Fur for the full induction of Dps expression in *Salmonella enterica*

549   serovar typhimurium. *J Microbiol Biotechnol* 17:1452–9.

550   47.   Faulkner MJ, Helmann JD. Peroxide stress elicits adaptive changes in bacterial metal ion

551   homeostasis. *Antioxid Redox Signal* 15:175-189.

552   48.   Calhoun LN, Kwon YM. 2011. Structure, function and regulation of the DNA-binding

553   protein Dps and its role in acid and oxidative stress resistance in *Escherichia coli*: A

554   review. *J Appl Microbiol* 110:375-386.

49.   Frenkiel-Krispin D, Levin-Zaidman S, Shimoni E, Wolf SG, Wachtel EJ, Arad T, Finkel

SE, Kolter R, Minsky A. 2001. Regulated phase transitions of bacterial chromatin: a non-

enzymatic pathway for generic DNA protection. *EMBO J* 20:1184–91.

50.   Wolf SG, Frenkiel D, Arad T, Finkel SE, Kolter R, Minsky A. 1999. DNA protection by

stress-induced biocrystallization. *Nature* 400:83–5.

51.   Nair S, Finkel SE. 2004. Dps protects cells against multiple stresses during stationary

phase. *J Bacteriol* 186:4192–8.

52.   Grant RA, Filman DJ, Finkel SE, Kolter R, Hogle JM. 1998. The crystal structure of Dps,

a ferritin homolog that binds and protects DNA. *Nat Struct Biol* 5:294–303.

53.   Orban K, Finkel SE. 2022. Dps is a universally conserved dual-action DNA-binding and

ferritin protein. *J Bacteriol* 204:e0003622.

54.   Yamamoto Y, Poole LB, Hantgan RR, Kamio Y. 2002. An iron-binding protein, Dpr,

from Streptococ*cus mutans* prevents iron-dependent hydroxyl radical formation in vitro. *J*

Bacteriol 184:2931–2939.

55.   Tsou CC, Chiang-Ni C, Lin YS, Chuang WJ, Lin MT, Liu CC, Wu JJ. 2008. An iron-

binding protein, Dpr, decreases hydrogen peroxide stress and protects *Streptococcus*

pyogenes against multiple stresses. *Infect Immun* 76:4038–4045.

56.   Poole LB, Higuchi M, Shimada M, Calzi ML, Kamio Y. 2000. *Streptococcus mutans*

H_2O_2-forming NADH oxidase is an alkyl hydroperoxide reductase protein. *Free Radic*

Biol Med 28:108-120.

57.   Poyart C, Pellegrini E, Gaillot O, Boumaila C, Baptista M, Trieu-Cuot P. 2001.

Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of

Streptococcus agalactiae. *Infect Immun* 69:5098–5106.

58.   Rhodes D V., Crump KE, Makhlynets O, Snyder M, Ge X, Xu P, Stubbe J, Kitten T.

2014. Genetic characterization and role in virulence of the ribonucleotide reductases of

Streptococcus sanguinis. *J Biol Chem* 289:6273–6287.

581